We have recently developed a next-generation radioimmunoconjugate (RIC) based on the beta-emitting radionuclide 177 Lu chelated to p-SCN-Bn-DOTA (satetraxetan) conjugated to the an- 9-12 177 Lu-lilotomab has shown strong anti-tumour effect in preclinical models 9, 13 and in a completed phase 1/2a clinical trial. 14 To be effective, rituximab depends on selective expression of a sufficient number of CD20 antigens per cell. [1] [2] [3] [4] Treatment with highdose External Beam Radiation (EBR) upregulates antigens such as HER2, EGFR and CD20 in cancer cells, [15] [16] [17] and an increase in the antigen expression is correlated with an increase in anti-tumour activity of immunotherapies targeting these antigens. 15, 18, 19 Patients treated with low-dose EBR immediately prior to anti-CD20 radioimmunotherapy (RIT) with ibritumomab tiuxetan conjugated to Yttrium-90 had longer freedom from progression (FFP) than patients only treated with RIT with no additional toxicity. 20 The authors hypothesised that the superior therapeutic effect of anti-CD20 RIT after EBR was due to surface upregulation of CD20 after EBR. We wanted to study if the selectively delivered low-dose rate radiation from Lu-lilotomab than to un-treated cells.
| MATERIAL S AND ME THODS

| Labelling of lilotomab with 177 Lu
The chelator (p-SCN-Bn-DOTA, Macrocyclics, TX, USA) was dis- 
| Cell lines
Cell suspensions of lymphoma cell lines Daudi (Burkitt's lymphoma),
and Rec-1 (Mantle Cell Lymphoma, both acquired from ATCC) were grown in RPMI 1640 medium (PAA, Linz, Austria) supplemented with 10% heat-inactivated FCS (PAA), 1% L-glutamine (PAA) and 1% penicillin-streptomycin (PAA) in a humid atmosphere with 95% air/5% CO 2 and maintained in exponential growth phase through sub-culturing every 2-4 days.
| Immunoreactive fraction of 177 Lu-lilotomab
The immunoreactivity of the radioimmunoconjugates was measured using NHL Ramos cells and a one point modified Lindmo method. 21, 22 The cell concentration used was 75 million cells/mL. The immunoreactivity of the conjugates was between 60% and 82%. The facility is inspected regularly by the District veterinary office. 24 and was chosen so that the therapeutic effect of the single treatment was suboptimal in order to be able to detect an increased effect of the combination with rituximab. The same thinking guided the choice of rituximab dosage which was chosen based on published data on similar animal models. [25] [26] [27] [28] [29] [30] Pre-dosing with 200 μg IgG2 a was given one day before the first treatment injection to reduce non-specific uptake of mAbs. Treatments were given every 3-4 days. Nine to ten mice (bearing a total of 16-18 tumours) were used per group. Tumour volumes were measured 2-3 times a week, and weekly after study day 100 by measuring the shortest (a) and longest (b) perpendicular diameters using an electronic calliper and the equation: Volume = (a 2 b)/2. Body weight was measured every 2-3 days and weekly after study day 100 or more often when mice showed signs of sickness. Mice that were still alive at the end of the study (day 222) were necropsied, and key organs (lungs, liver, spleen, kidneys, stomach, ovaries, brain, femur and skull) were harvested for histopathological evaluation.
| Animal models
| Therapy studies
The therapeutic effect of the combination in the Rec-1 i.v. model was performed in a blinded study using one injection of 40 MBq/ kg 177 Lu-lilotomab, one injection of 100 μg of rituximab per mouse (around 5 mg/kg for a 20 g mouse) or NaCl ( Table 2 ). The activity of 177 Lu-lilotomab used was approximately 50% of the maximum tolerated dosage (MTD) 24 and was chosen so that the therapeutic effect of the single treatment was suboptimal in order to be able to detect an increased effect of the combination with rituximab. The same thinking guided the choice of rituximab dosage which was chosen based on published data on similar animal models. 31, 32 Nine to ten mice were used per group. Mice were administered with the first treatment on day 8; study day 0 was set at injection of tumour cells.
The second treatment was given 5 days later. The mice were weighed at least twice a week, and they were inspected at least once daily for clinical signs of disease. When clinical signs of the disease were apparent, an abdominal palpation for tumours was preformed once/ twice a week. At termination, all mice were necropsied and the following organs were collected for histopathological evaluation: skull, brain, femur, liver, spleen, easily accessible lymph nodes, uterus, ovaries, the whole vertebrae and tumours. The organs were fixed in 10% buffered formalin and further processed for histopathological evaluation. Blood was drawn from the animals every 3 weeks until week 9 for haematology analysis. Blood samples (no more than 10% of the total blood volume) were drawn from vena facialis and collected into 100 μL EDTA-coated tubes (Microvette®100 K3E, Sarsted). The tubes were turned/swirled for around 1 minute to ensure all EDTA was mixed well with the blood. White blood cells, platelets and red blood cells were counted on an automated haematology analyzer (MS4 analyzer from Melet Schloeing Laboratories, France). 
| Statistical analysis
Survival analysis was performed using log-rank test and the Holm- 
| Expression of cell surface CD20 in-vitro
The expression of the CD20 antigen was measured in the cell lines vs NaCl. Due to the low number of events (ie mice never reaching tumour diameter >20 mm and thus being censored at the end of the study) in the combination group, the test for interaction did not reach the threshold for significance (P = 0.078). In addition, the spread in the survival of mice treated with only rituximab and the dependence of HR with time might have also contributed to the lack of statistical significance.
Average body weight was similar in all treatment groups (data not shown). There were, however, some mice in the combination groups that experienced body weight loss and other clinical symptoms of sickness and discomfort (Table 5 ). Histopathological analysis of mice euthanised at the end of the study showed no evidence of longterm toxicity associated with the combination treatments. The body weight loss observed after day 100 was probably due to normal aging of the mice. Figure 3) . However, the differences were only statistically significant for the comparison with NaCl (Table 6 ). The median survival was more than 132 days (106% increase as compared to NaCl control) for the combination while it was 92 days (44% increase) for 177 Lu-lilotomab alone and 75 days (15% increase) for rituximab alone ( Table 6 ). The HR T found using the Cox proportional hazards regression model was 0.104 (Table 4) 
| Additive effect of
E 4 Output from cox regression model from study in nude mice with s.c. Daudi xenografts and tumour diameter equal or larger than 20 mm as end-point and from study in SCID mice with i.v. injected Rec-1 cells and euthanasia due to sickness, discomfort or palpable tumour diameter
| Expression of cell surface CD20 in-vitro
The 
| D ISCUSS I ON
The use of radioimmunotherapy has been approved as a therapeutic option in cancer therapy for several years. 35 There might be other mechanisms behind the synergistic effect.
Radioimmunotherapy has been shown to increase the permeability of tumour vasculature 37 which might lead to better tumour uptake of antibodies. Moreover, CD20 binding of rituximab has shown to improve internalisation of an anti-CD37 antibody drug conjugate (ADC) thereby enhancing its efficacy. 38 The efficacy of 177 Lulilotomab might therefore be also increased if the same enhanced internalisation occurs. In addition, it has been shown that radiation induces immunogenic modulation of tumour cells. [39] [40] [41] There might be several reasons for the lower effect of the com- It is important to notice that 177 Lu-lilotomab does not bind to murine CD37 (data not shown) and rituximab does not bind to murine CD20. 42, 43 Therefore, in the mouse models, there is not non- CD20 downregulation after treatment with rituximab has been repeatedly observed in rituximab resistant patients [44] [45] [46] shown to increase rituximab binding to NHL cells, we hypothesise that treatment with 177 Lu-lilotomab could be potentially used to revert downregulation of CD20 and resistance to rituximab. Further studies using rituximab resistant cell lines will be performed to explore this hypothesis.
| CON CLUS ION
We have shown that treatment of NHL in vivo with 177 Lu-lilotomab results in an increased tumour suppression of anti-CD20 immunotherapy and improved survival. We have also shown that the interaction can be synergistic. If the same effect is confirmed in clinical studies, it could change the way RIT and CD20 immunotherapy would be used in the future.
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